Engimmune Therapeutics and LSN GmbH

Engimmune Therapeutics is targeting malignant and inflamed tissue with soluble TCRs 

TCR-based therapies are an emerging class of drugs leveraging highly specific recognition of tumour and tissue antigens to enable precision immunotherapy.  

In oncology, soluble TCR approaches provide a unique mechanism of action that addresses many obstacles associated with targeting solid tumours, including: 

• Targeting of intracellular antigens

• High-affinity binding to low-copy number peptide targets

• Tumour-targeted biodistribution

• Sustained recruitment of effector immune cells

In immune-mediated disease, soluble TCRs enable high affinity targeting of tissue antigens to suppress the immune system at the site of disease, facilitating: 

• Biodistribution targeted to inflamed tissues

• T cell inhibition at the site of inflammation

• Blockade of autoantigen recognition

• Long serum half-life for less frequent dosing